Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAF effect on residual intrathecal immune activation
2015-004427-31Phase 4Completed
- Sponsor
- University of Gothenburg
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by University of Gothenburg. Primary endpoint: Change in cerebrospinal fluid viral load or intrathecal immune activation. Started Jan 2016; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2015-004427-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004427-31.